SOURCE: Regen BioPharma Inc.

April 07, 2015 10:19 ET

Regen BioPharma Inc. to Present Multiple Presentations at the 13th International Symposium on Myelodysplastic Syndromes

Company Has Two of Its Abstracts Accepted and Upgraded for Oral Presentation, With a Third Abstract Accepted for Poster Presentation on Myelodysplastic Syndrome Related Topics

SAN DIEGO, CA--(Marketwired - Apr 7, 2015) -  Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today that the 13th International Symposium on Myelodysplastic Syndromes has accepted three presentations prepared by Regen BioPharma Inc. The accepted abstracts highlight the work being done in the Company's area of expertise in Aplastic Anemia and Myelodysplastic Syndrome. The link to the conference is http://mds.kenes.com 

Myelodysplastic Syndrome is a disease of bone marrow failure, where blood cells fail to form because bone marrow stem cells fail to differentiate. The Company has filed one IND in this space on HemaXellerate treatment for aplastic anemia and is working on preclinical development of DiffronC, an siRNA based therapeutic targeting cancer stem cell genes involved in blood cell differentiation.

The three presentations are:

  • HEMAXELLERATE I™, AUTOLOGOUS ADIPOSE STROMAL VASCULAR FRACTION CELLS, FOR SEVERE APLASTIC ANEMIA

  • NR2F6 (EAR-2) IS A NOVEL LEUKEMIA AND MDS ONCOGENE, OVER-EXPRESSED IN PATIENTS, THAT INHIBITS HEMATOPOIETIC DIFFERENTIATION AND BLOCKS ERYTHROPOIETIC DIFFERENTIATION AT THE PROERYTHROCYTE STAGE

  • TECHNIQUE FOR ESTABLISHMENT OF LONG TERM IN VITRO CULTURES OF PRIMARY MDS CELLS

Regen's Chairman & CEO David Koos stated, "These three presentations represent an exciting turning point for the Company. We are gaining credibility and exposure in our fields of research among the top biotechnology scientists around the world. This should lead to potential collaborations that aid in our future progress."

ABOUT REGEN BIOPHARMA INC.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) and (OTC PINK: RGBP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.

Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact Information

  • CONTACT INFORMATION
    Regen BioPharma Inc.
    David R. Koos, PhD
    Chairman & Chief Executive Officer
    619-702-1404 Phone
    619-330-2328 Fax
    www.regenbiopharma.com